Skip to Main Content

Try STAT+ TODAY

cancer

Most Read

On Target Angus Chen

STAT Plus: In the search for therapies for solid tumors, companies are turning to a novel target: claudin-6

Biotech Jason Mast

STAT Plus: After four years of big talk, mega startup Sana prepares to deliver some data

Biotech Jonathan Wosen

STAT Plus: Liquid biopsy study suggests a better way to decide which colorectal cancer patients need chemo

Biotech Jonathan Wosen

STAT Plus: Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’

Biotech Jonathan Wosen

STAT Plus: BioNTech CEO lays out vision for how mRNA and AI can power personalized medicine

Politics John Wilkerson

STAT Plus: Medicare paves the way for CAR-T in doctors offices

Pharmalot Ed Silverman

Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug

First Opinion Nathan Vardi

Is the golden age of biotech stocks over?

All Coverage

Health Tech Casey Ross

STAT Plus: As more never-smokers develop lung cancer, researchers test an AI model to predict patient risk

Biotech Allison DeAngelis

STAT Plus: How one private biotech seized on JPM to emerge from stealth and tell its story

advertisement

On Target Angus Chen

STAT Plus: Is mesothelin a key to tackling solid tumors? Some biotech companies are betting that it is

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score

Exclusive Jason Mast

STAT Plus: Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval

Biotech Jason Mast

STAT Plus: Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success

Health Angus Chen

STAT Plus: Parker Institute extends ‘crazy idea’ funding to two more cancer centers

Biotech Jason Mast

STAT Plus: Kite to buy Tmunity Therapeutics, Carl June’s troubled CAR-T startup

Biotech Adam Feuerstein

STAT Plus: Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in mid-stage study

Biotech Jonathan Wosen

STAT Plus: Guardant Health trial of colon cancer liquid biopsy test disappoints observers

Biotech Damian Garde and Angus Chen

Virtual Event: “ASH Recap, Live!” 2022

In the Lab Jonathan Wosen

Study offers a genetic explanation for why some drugs trigger a deadly brain disease

Health Angus Chen

STAT Plus: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia

Biotech Matthew Herper

STAT Plus: Moderna says cancer vaccine reduces melanoma’s return by 44%

Biotech Adam Feuerstein

STAT Plus: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed

Biotech Adam Feuerstein

STAT Plus: Affimed’s natural killer cell therapy has murky path forward despite encouraging results

Biotech Angus Chen

STAT Plus: Novartis develops CAR-T therapy that can be made in a fraction of the standard time

Health Angus Chen

STAT Plus: ‘We’ve got a new target’: Bispecific antibody for multiple myeloma succeeds in mid-stage trial

Health Angus Chen

STAT Plus: Bone marrow transplant patients could be spared from ‘bland’ diet, study finds

Biotech Adam Feuerstein

STAT Plus: Emerging class of genetically targeted drugs induce remissions in leukemia patients

Biotech Adam Feuerstein

STAT Plus: Progress report on Adicet’s ‘gamma-delta’ T cell therapy shows mixed results on durability of remissions

Health Carla K. Johnson — Associated Press

Pausing breast cancer treatment for pregnancy appears safe

Hospitals Bob Herman

Cancer patients endure an overlooked financial burden: hospital parking fees

In the Lab Angus Chen

STAT Plus: In ‘landmark’ study, cell therapy exceeds expectations in melanoma patients

Health Jayne Williamson-Lee

‘I question what I know’: Top cancer specialist Otis Brawley on valuing orthodoxy in medicine